MedTrace Logo

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

NCT00153049 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 583

Last updated 2013-11-08

No results posted yet for this study

Summary

1. To investigate the dose response of the combination therapy, Telmisartan and Hydrochlorothiazide for the Japanese patients with Essential Hypertension.
2. To compare this dose response with that in the US study.

Conditions

Interventions

DRUG

Telmisartan

DRUG

Hydrochlorothiazide

DRUG

Telmisartan + Hydrochlorothiazide

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · Nippon Boehringer Ingelheim Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00153049 on ClinicalTrials.gov